PL440293A1 - Application of carlina oxide for prevention of SARS-CoV-2 virus infection and treatment of COVID-19 disease - Google Patents
Application of carlina oxide for prevention of SARS-CoV-2 virus infection and treatment of COVID-19 diseaseInfo
- Publication number
- PL440293A1 PL440293A1 PL440293A PL44029322A PL440293A1 PL 440293 A1 PL440293 A1 PL 440293A1 PL 440293 A PL440293 A PL 440293A PL 44029322 A PL44029322 A PL 44029322A PL 440293 A1 PL440293 A1 PL 440293A1
- Authority
- PL
- Poland
- Prior art keywords
- oxide
- covid
- treatment
- carlina
- disease
- Prior art date
Links
- 208000025721 COVID-19 Diseases 0.000 title abstract 2
- 241001678559 COVID-19 virus Species 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 230000009385 viral infection Effects 0.000 title abstract 2
- ICRHFCVRNWSKQH-UHFFFAOYSA-N Carlina oxide Chemical compound C=1C=CC=CC=1CC#CC1=CC=CO1 ICRHFCVRNWSKQH-UHFFFAOYSA-N 0.000 title 2
- HOWWJRHBQZWPKM-UHFFFAOYSA-N Carlinoxide Natural products C(C#CC1CCCO1)c2ccccc2 HOWWJRHBQZWPKM-UHFFFAOYSA-N 0.000 abstract 4
- 241000207965 Acanthaceae Species 0.000 abstract 1
- 241000132043 Carlina Species 0.000 abstract 1
- 240000000614 Carlina acanthifolia Species 0.000 abstract 1
- 240000001789 Carlina acaulis Species 0.000 abstract 1
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 abstract 1
- 241000208809 Carthamus Species 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 241000196324 Embryophyta Species 0.000 abstract 1
- YSFNIVKHYKBKHI-SAETXWKOSA-N [(1r,4ar,7s)-7-ethenyl-1,4a,7-trimethyl-3,4,6,8,8a,9,10,10a-octahydro-2h-phenanthren-1-yl]methanol Chemical compound OC[C@]1(C)CCC[C@@]2(C)C3=CC[C@@](C=C)(C)CC3CCC21 YSFNIVKHYKBKHI-SAETXWKOSA-N 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 abstract 1
- 235000015872 dietary supplement Nutrition 0.000 abstract 1
- YSFNIVKHYKBKHI-UHFFFAOYSA-N ent-isopimar-9(11)-15-diene-19-ol Natural products OCC1(C)CCCC2(C)C3=CCC(C=C)(C)CC3CCC21 YSFNIVKHYKBKHI-UHFFFAOYSA-N 0.000 abstract 1
- 229920001197 polyacetylene Polymers 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Istotą wynalazku jest zastosowanie tlenku carlina - naturalnego poliacetylenu do profilaktyki zakażeń wirusem SARS CoV-2 oraz leczenia choroby COVID-19, korzystnie w postaci ekstraktu. Zastosowany tlenek carlina izolowany jest z korzeni roślin - gatunków z rodzaju Carlina L. (dziewięćsił), Carthamus (krokosz), korzystnie izolowany z korzeni C. acaulis L. lub izolowany z korzeni C. acanthifolia L. (dziewięćsiłu akantolistnego). Zastosowany tlenek carlina korzystnie uzyskiwany jest syntetycznie. Zgłoszenie obejmuje też zastosowanie tlenku carlina jako dodatku do suplementów diety, stosowanych we wspomaganiu leczenia COVID.The essence of the invention is the use of carlin oxide - a natural polyacetylene for the prevention of SARS CoV-2 virus infections and the treatment of COVID-19 disease, preferably in the form of an extract. The carlin oxide used is isolated from the roots of plants - species of the genus Carlina L. (acanthus), Carthamus (safflower), preferably isolated from the roots of C. acaulis L. or isolated from the roots of C. acanthifolia L. (acanthol leaves). The carlin oxide used is preferably synthetically obtained. The application also covers the use of carlin oxide as an additive to dietary supplements used to support the treatment of COVID.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL440293A PL245100B1 (en) | 2022-02-02 | 2022-02-02 | The use of carlin oxide for the prevention of SARS-CoV-2 virus infections and the treatment of COVID-19 disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL440293A PL245100B1 (en) | 2022-02-02 | 2022-02-02 | The use of carlin oxide for the prevention of SARS-CoV-2 virus infections and the treatment of COVID-19 disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL440293A1 true PL440293A1 (en) | 2022-07-25 |
| PL245100B1 PL245100B1 (en) | 2024-05-13 |
Family
ID=83721649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL440293A PL245100B1 (en) | 2022-02-02 | 2022-02-02 | The use of carlin oxide for the prevention of SARS-CoV-2 virus infections and the treatment of COVID-19 disease |
Country Status (1)
| Country | Link |
|---|---|
| PL (1) | PL245100B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL444710A1 (en) * | 2023-04-29 | 2024-11-04 | Uniwersytet Medyczny W Lublinie | Pharmaceutical composition and its use in the prevention and treatment of upper respiratory tract infection caused by the SARS-CoV-2 virus and a method for producing preparations used in the prevention and treatment of SARS-CoV-2 virus infection |
-
2022
- 2022-02-02 PL PL440293A patent/PL245100B1/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL444710A1 (en) * | 2023-04-29 | 2024-11-04 | Uniwersytet Medyczny W Lublinie | Pharmaceutical composition and its use in the prevention and treatment of upper respiratory tract infection caused by the SARS-CoV-2 virus and a method for producing preparations used in the prevention and treatment of SARS-CoV-2 virus infection |
Also Published As
| Publication number | Publication date |
|---|---|
| PL245100B1 (en) | 2024-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20061912L (en) | Vaccine compositions comprising an interleukin 18 and saponin adjuvant system | |
| MX2023000411A (en) | Sars-cov-2 and influenza combination vaccine. | |
| PH12022550438A1 (en) | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | |
| MY208001A (en) | A subunit vaccine for treatment or prevention of a respiratory tract infection | |
| BR112022005883A2 (en) | Fluoride-free anticaries oral treatment compositions | |
| MX2022015071A (en) | ANTIBODY MOLECULES AGAINST THE BK VIRUS. | |
| BR112022004397A2 (en) | Oral care compositions comprising hop beta acids and amino acids | |
| PL440293A1 (en) | Application of carlina oxide for prevention of SARS-CoV-2 virus infection and treatment of COVID-19 disease | |
| MX2023006146A (en) | Designed bacterial compositions for treating graft-versus-host-di sease. | |
| BR112022024226A2 (en) | METHODS FOR TREATING OR PREVENTING A SUDDEN ACUTE RESPIRATORY SYNDROME CORONAVIRUS INFECTION, FOR TREATING AN ACUTE RESPIRATORY DISTRESS SYNDROME, AND FOR TREATING AN IMMUNE DYSFUNCTION OR HYPERINFLAMMATORY CONDITION IN A MAMMAL SUBJECT, ANTIVIRAL COMPOSITION OR KIT FOR USE IN HUMAN SUBJECTS, AND, COMPOSITION PHARMACEUTICAL OR KIT FOR USE IN THE PREVENTION OR TREATMENT OF ACUTE RESPIRATORY SYNDROME IN A MAMMAL SUBJECT | |
| BR112022020441A2 (en) | COMPOSITIONS COMPRISING NANOPARTICLES, MANUFACTURING METHOD AND USES THEREOF | |
| EA202091690A1 (en) | IMMUNOGENIC COMPOSITION CONTAINING STAPHYLOCOCCAL ANTIGENS | |
| WO2005028496A3 (en) | Vaccine for treatment and prevention of herpes simplex virus infection | |
| BR112023000650A2 (en) | RECOMBINANT VACCINIA VIRUS | |
| MX2022012165A (en) | INTERACTION OF SARS-COV-2 PROTEINS WITH MOLECULAR AND CELLULAR MECHANISMS OF HOST CELLS AND FORMULATIONS TO TREAT COVID-19. | |
| JOP20240233A1 (en) | Mutant CD24 proteins and their uses in cancer prevention and treatment | |
| BR112023003135A2 (en) | SILYBUM MARIANUM (L.) GAERTN OIL. IN STRENGTHENING THE SKIN BARRIER FUNCTION | |
| PH12022552300A1 (en) | Cpg-adjuvanted sars-cov-2 virus vaccine | |
| PL445779A1 (en) | The use of essential oil from the roots of Carlina vulgaris L. for the prevention of SARS-CoV-2 virus infections and the treatment of COVID-19 disease | |
| MX2023002109A (en) | Viral inhibitors. | |
| MX2024005962A (en) | IMMUNOGENETIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USING THESE | |
| ATE345126T1 (en) | SESQUITERPENOID DERIVATIVES WITH ADIPOCYTE DIFFERENTIATION-INHIBITING EFFECT | |
| MX2023006076A (en) | CANNABINOID DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATION AND/OR PAIN AND/OR OBESITY. | |
| PL420267A1 (en) | Polyporoid mushroom extract, a composition containing this extract and its use | |
| CL2021001889A1 (en) | Methods to purify the extract of an allergen |